Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Rhea-AI Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.
The company will host a conference call and live webcast at 8:00 am ET the same day to review the Phase 1a safety and tolerability data; a replay will be available on the Corbus website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRBP gained 1.58%, reflecting a mild positive market reaction. Argus tracked a peak move of +25.7% during that session. Argus tracked a trough of -30.9% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $180M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology showed mixed moves: declines in BMEA (-0.74%) and FATE (-2.78%), while PYXS, EQ, and KALA rose between 3.37% and 4.92%, suggesting stock-specific factors for CRBP.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Earnings and update | Positive | +7.4% | Q3 2025 report, CRB-701 data, funding runway and upcoming CRB-913 readout. |
| Nov 06 | Investor conferences | Neutral | -4.2% | Participation in three investor conferences with webcasted presentations and meetings. |
| Oct 31 | Public offering priced | Negative | -26.1% | Pricing of equity and pre-funded warrant offering to raise about $75M. |
| Oct 30 | Offering proposed | Negative | -2.5% | Announcement of proposed underwritten public offering and potential overallotment. |
| Oct 14 | Conference clinical data | Neutral | -0.4% | Plan to present updated CRB-701 Phase 1/2 data at ESMO 2025. |
Recent history shows aligned reactions: financing news led to large declines, while data and corporate updates saw modest gains or contained moves, indicating sensitivity to dilution and funding events.
Over the last few months, Corbus reported Q3 2025 results and a CRB-701 data update on Nov 12, with the stock rising 7.39%. Two late-October financing announcements, including a $75M public offering, led to declines of 26.09% and 2.49%. Conference and clinical data presentations in mid-October had limited price impact. Today’s planned CRB-913 Phase 1a readout follows earlier guidance that this SAD/MAD data would arrive by end of 2025.
Market Pulse Summary
This announcement schedules the first Phase 1a SAD/MAD data for oral CB1 inverse agonist CRB-913, with a webcast on December 11, 2025 at 8:00 am ET. Earlier disclosures tied this obesity program to a broader, well-funded pipeline, supported by recent capital raises. Investors may focus on safety, dosing, and any directional efficacy signals, alongside how this candidate complements existing oncology assets and previously communicated development timelines.
Key Terms
phase 1a medical
single ascending dose medical
multiple ascending dose medical
inverse agonist medical
AI-generated analysis. Not financial advice.
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET
NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data.
To register for the webcast, click here . A replay will be available on the Corbus website.
About CRB-913
CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1). This is a recognized mechanism of action for weight loss, but the first generation of experimental drugs in this class was abandoned due to potential neuropsychiatric adverse event risks. CRB-913 is a highly peripherally restricted CB1 inverse agonist designed to have reduced brain penetration. Preclinical models have shown CRB-913 to be 15-fold less brain-penetrant than monlunabant (another experimental CB1 inverse agonist) and to have 50 times lower brain:plasma ratio than rimonabant (an extensively studied first-generation CB1 inverse agonist).
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
FAQ
When will Corbus (CRBP) release Phase 1a CRB-913 results?
What time is the Corbus (CRBP) conference call and webcast for CRB-913 data?
What does the Phase 1a study of CRB-913 include for CRBP?
How can investors access the Corbus (CRBP) CRB-913 webcast and replay?
Will Corbus (CRBP) discuss safety and tolerability in the December 11, 2025 call?
